PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29040827-1	2017	BACKGROUND: Accumulating evidence suggests that the FDA-approved serotonin 5-HT2C receptor agonist, lorcaserin (Belviq ), may be a promising candidate for the management of substance use disorders, including nicotine addiction.	Nicotine	208-216	5-hydroxytryptamine receptor 2C	Homo sapiens	65-90	
23184281-8	2013	CONCLUSIONS: These studies support the utility of 5-HT2C agonists as a therapeutic approach to treat nicotine dependence.	Nicotine	101-109	5-hydroxytryptamine receptor 2C	Homo sapiens	50-56	
24041919-4	2013	The availability of selective 5-HT2C agonists provides an opportunity to evaluate their potential as treatments for nicotine dependence or psychostimulant abuse, conditions for which there is significant medical need but only limited available treatment options.	Nicotine	116-124	5-hydroxytryptamine receptor 2C	Homo sapiens	30-36